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Abstract
Pten is a negative regulator of the Akt pathway, and its inactivation is believed to be an etiological factor in many
tumor types. Pten+/− mice are susceptible to a variety of spontaneous tumor types, depending on strain back-
ground. Pten+/− mice, in lung tumor–sensitive and –resistant background strains, were treated with a tobacco
carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), to determine whether allelic Pten deletion can co-
operate with NNK in carcinogenesis in lung or other tissues. In lung tumor–resistant C57BL/6 Pten+/− or +/+ mice,
NNK treatment did not lead to any lung tumors and did not increase the incidence or severity of tumors previously
reported for this strain. In contrast, in a lung tumor–susceptible pseudo–A/J strain, there was a dose-dependent
increase in lung tumor size in Pten+/− compared with +/+ mice, although there was no increase in multiplicity.
No other tumor types were observed in pseudo–A/J Pten+/− mice regardless of NNK treatment. Lung tumors
from these Pten+/− mice had K-ras mutations, retained Pten expression and had similar Akt pathway activation
as lung tumors from +/+ mice. Therefore, deletion of a single copy of Pten does not substantially add to the lung
tumor phenotype conferred by mutation of K-ras by NNK, and there is likely no selective advantage for loss of the
second Pten allele in lung tumor initiation.
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Introduction
Pten is a phosphatase whose inactivation is believed to be an etiologi-
cal factor in many human tumor types. Although Pten has homol-
ogy to protein tyrosine phosphatases, its primary substrates are 3′
phosphoinositides. In this respect, Pten acts as an antagonist to the
phosphoinositide 3-kinase (PI3K)–Akt pathway, which is frequently
activated and associated with poor prognosis in many tumor types
[1]. Pten mutation coupled with loss of heterozygosity is found at
a high frequency in endometrial, prostate, and high-grade glial tu-
mors [2]. Mutations occur most frequently but not exclusively within
the phosphatase domain of the protein, implicating the effects on
PI3K–Akt signaling as a primary tumor suppressor function of Pten.
Genetically engineered mice with germline deletion of a single
copy of Pten exhibit some of the same tumor types observed in
human patients with germline Pten mutation. Loss or reduction of
Pten protein is common in non–small cell lung cancer [3], as is Akt
activation [4], but it is unclear whether mutant or decreased Pten is a
risk factor for tobacco-related neoplasms. 4-(Methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK), a tobacco-specific nitrosamine,
which is the most potent carcinogen in tobacco smoke, has been
widely used to induce lung tumors in mice [5]. Both NNK treatment
and Pten mutation lead to Akt pathway activation in vitro and in vivo
[6,7]. In genetically engineered mouse models, lung-specific deletion
of Pten coupled with K-ras mutation led to a more malignant lung
tumor phenotype, although Akt is most likely a primary target for
mutant K-ras–mediated lung tumorigenesis [4,8,9].
Abbreviations: PI3K, phosphoinositide 3-kinase; NNK, 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone
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Lung carcinogenesis by NNK in mice is highly strain-dependent,
and only lung tumors have been described in susceptible strains.
However, other cancers have been associated with tobacco use in
humans, and there are no mouse models to investigate these. To
assess lung carcinogenesis and potentially other tumors types, we
treated Pten+/− mice in a lung tumor–susceptible (pseudo–A/J) or
lung tumor–resistant background (C57BL/6) with NNK. Pten+/−
pseudo–A/J mice did not show an increase in lung tumor suscep-
tibility, although there was a dose-dependent increase in tumor size.
Surprisingly, no other tumors were observed in these mice up to
30 weeks of age. Nearly all lung tumors from NNK-treated Pten+/−
and +/+ mice had K-ras mutations in exon 1. Similar Akt pathway ac-
tivation was observed in both groups, although tumors from Pten+/−
mice showed decreased, but not absent, Pten expression. In a resis-
tant strain background, C57BL/6, Pten+/− mice developed adrenal,
endometrial, and prostate tumors irrespective of NNK treatment,
but no lung tumors. These results indicate that loss of a single copy
of Pten does not increase tobacco carcinogen sensitivity, perhaps due
to the redundancy of signaling pathways induced by Pten hetero-
zygosity and K-ras mutation.
Materials and Methods
Mouse Husbandry and Carcinogen Treatment
Pten+/− mice [10] in a C57BL/6 background (eight backcrosses)
were obtained from the Mouse Models of Human Cancer Consor-
tium and had two copies of C57BL/6 K-ras allele as determined by
polymerase chain reaction (PCR). These mice were backcrossed twice
with A/J mice, which are susceptible to lung tumors induced by
NNK treatment. Lung tumor–susceptible mice carried two copies
of the wild type A/J K-ras allele and are referred to as pseudo–A/J.
Pten+/− pseudo–A/J were crossed with A/J and +/+ and +/− litter-
mates were used for lung tumorigenesis studies. Mice were injected
intraperitoneally with NNK (Eagle Pitcher) at 100 mg/kg beginning
at 6 weeks of age with either a single dose or three doses at weekly
intervals. At 24 weeks after a single dose or 16 weeks after the first of
three doses, mice were killed by cervical dislocation, lungs inflated
with 10% neutral-buffered formalin, and tissues fixed in the same.
The following day, lung lobes were separated and surface lung tumors
were counted and measured with a dissecting microscope. Untreated
mice were also killed at the same age. Pten+/− mice were also crossed
with C57BL/6 mice, and the progenies were used for single-dose
NNK carcinogenesis but with an end point at 30 weeks after treat-
ment. Data were analyzed using Prism (GraphPad Software, Inc, San
Diego, CA) using unpaired t tests.
Tissues were processed to paraffin, sectioned, and stained with
hematoxylin and eosin. All tissues were evaluated by a board-certified
veterinary pathologist. Tissues evaluated included adrenal glands, cer-
vical lymph nodes, spleen, thymus, pancreas, kidneys, lungs, heart,
liver, bladder, bone marrow, colon, intestines, brain, and male and
female reproductive organs.
Pten genotype was determined by PCR from tail clips [11]. Briefly,
5 mm of the tail tip was lysed overnight in 100 μl of 100 mM Tris,
pH 8, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, and 100 μg/ml pro-
teinase K. The following day, 300 μl of water was added, and samples
were boiled for 10 minutes before PCR on 1 μl for each sample. K-ras
allele strain contribution was determined by PCR for Kras_37 [12].
The A/J allele yielded a 91-bp PCR product, whereas the C57BL/6
allele yielded a 128-bp product.
Analysis of K-ras Mutations
K-ras mutations were detected in individual lung tumors using the
Surveyor Mutation Detection kit (Transgenomic, Inc., Omaha, NE).
After paraffin removal with xylene, tumors were excised from un-
stained 20-μm sections using razor blades and a dissecting microscope.
Tumors were identified on adjacent sections stained with hematoxylin
and eosin and were clearly visible on unstained sections. Tumor tissue
was digested in 50 μl of 100 mM Tris, pH 8.0, 5 mM EDTA, 0.2%
SDS, 200 mMNaCl, and 100 μg/ml proteinase K overnight at 55°C.
Approximately 50 μl of water was added, samples were boiled, and 5 μl
was used for amplification of K-ras exons 1 and 2 as described pre-
viously [13]. Internal primers were used for a second round of am-
plification to generate single bands for the mutation assay (exon 1,
5′-gtaaggcctgctgaaaatgact-3′ and 5′-gactgtagagcagcgttacct-3′ generat-
ing a product of 146 bp; exon 2, 5′-caagtagtaattgatggagaaacctgt-3′
and 5′-caacttaaacccacctataatggtga-3′ generating a product of 178 bp).
Tumor PCR products were mixed with PCR product from A/J mouse
tail DNA. Cleavage products of approximately 94 and 52 bp were
expected for mutations at codon 12 in exon 1 of K-ras, whereas cleav-
age products of 121 and 67 bp were expected for mutations at codon
61 of exon 2.
Immunohistochemistry for Pten and Akt Pathway Status
Pten, pS473-Akt, and pS235/236 ribosomal S6 expression in lung
tumors was determined by immunohistochemistry as described pre-
viously [1] with the following exceptions. A Pten rabbit monoclonal
antibody (Cell Signaling Technology, Danvers, MA) and an IR800–
anti-rabbit secondary (Invitrogen, Carlsbad, CA) was used to quantify
Pten. Samples were counterstained with the DNA stain, To-Pro3-
iodide (Invitrogen), which emits in the IR700 channel, and were
scanned on an Odyssey (Licor Biosciences, Lincoln, NE) infrared scan-
ner at 21-μm resolution. Relative Pten expression was determined as
the relative ratio of Pten signal to To-pro3-iodide signal. Tumor loca-
tions were verified by comparison to adjacent sections stained with
hematoxylin and eosin. Immunohistochemistry for pS473-Akt and
pS235/236 ribosomal S6 protein (antibodies 3787 and 4857; Cell
Signaling Technology) were performed as described previously. Stain-
ing was scored as absent (0), mild (1), moderate (2), or strong (3).
Staining index was determined by summing the (fraction of cells
staining) × (intensity) as described previously [1].
Results
Development of Lung Tumor–Susceptible and –Resistant
Pten+/− Mice
Pten+/− mice were treated with a tobacco carcinogen to determine
whether allelic loss of Pten might confer increased risk for tumors
with a known tobacco-related component. However, strain-specific
effects of genetically modified mice are common [14] and Pten+/−
mice develop a different spectrum of tumors depending on strain
background [10,15–17]. In addition, both spontaneous and NNK-
induced lung tumors are strain-dependent, with A/J being the most
susceptible strain, conferred by the K-ras allele [18,19]. To make
pure C57BL/6 Pten+/− mice susceptible to lung tumorigenesis, they
were bred with A/J mice, and Pten+/− mice carrying the susceptible
A/J K-ras allele were selected for this study. These pseudo–A/J and
C57BL/6 Pten+/− mice were treated with NNK because we expected
different tumor spectrums for each background strain.
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Lung Tumorigenesis in Pseudo–A/J Pten+/− Mice
Consistent with the inbred A/J strain, pseudo–A/J mice developed
both spontaneous and NNK-induced lung tumors, although with
somewhat lower multiplicity than observed for inbred A/J mice (Fig-
ure 1) [1]. At 24 weeks after a single dose of NNK (at 30 weeks of
age), nearly all +/+ and Pten+/− mice had developed at least one sur-
face lung tumor, which is in contrast to the spontaneous group, most
of which had no tumors. Multiplicity was similar for +/+ and Pten+/−
mice within both the NNK-treated and untreated groups (Figure 1A).
In addition, there was no significant difference in tumor size be-
tween the Pten+/− and +/+ mice (Figure 1B). Due to the low lung
tumor multiplicity in this study (approximately 2/mouse), a new co-
hort was treated with three doses of NNK at weekly intervals and
killed 16 weeks after the first dose (at 22 weeks of age; Figure 2).
More lung tumors were observed in both +/+ and Pten+/− groups
with three doses of NNK when compared with a single dose
(a nine-fold increase for +/+). However, in the three-dose group,
Pten+/− mice developed significantly fewer lung tumors compared
with +/+ littermates (Figure 2A). Individual tumor size, however,
was increased in the Pten+/− mice and averaged 40% larger by
Figure 2. Pten+/− mice develop larger but increased numbers of lung tumors with three doses of NNK. Surface lung tumor multiplicity
and tumor size from pseudo–A/J Pten+/− and +/+ littermates 16 weeks after initial treatment with three doses of 100 mg/kg NNK
administered weekly starting at 6 weeks of age. (A) Each point represents a single mouse. (B) Tumor volume is per individual tumor
and is presented as mean ± 95% confidence interval for 214 and 148 lung tumors from Pten+/+ and +/− mice, respectively. This
cohort consisted of 4 +/+ females, 8 +/+ males, 6 Pten+/− females, and 11 Pten+/− males.
Figure 1. Pten+/− mice do not have enhanced susceptibility to either spontaneous or NNK-induced lung tumors. Surface lung tumor
multiplicity and tumor size from pseudo–A/J Pten+/− and +/+ littermates 24 weeks after treatment with 100 mg/kg NNK at 6 weeks of
age or untreated. (A) Each point represents a single mouse. (B) Tumor volume is per individual tumor. The spontaneous cohort consisted
of two +/+ females, four +/+ males, two Pten+/− females, six Pten+/−males. The NNK-treated cohort consisted of four +/+ females,
four +/+ males, eight Pten+/− females, and seven Pten+/− males. All P values in this and subsequent figures were obtained using an
unpaired t test.
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volume (Figure 2B). There were no differences between lung tumor
incidence, multiplicity, and size between male and female Pten+/−
mice (data not shown).
Lack of Lung Tumors in Pten+/− Mice in a Resistant
Strain Background
C57BL/6 is one of the most lung tumor–resistant strains of mice
[18]. To determine possible strain-dependent effects of NNK, mice
in a C57BL/6 background (more than eight backcrosses with C57BL/
6) were treated with a single dose of NNK using an end point at
30 weeks after treatment. No lung tumors were observed in any of
these mice, reflecting the relative lung tumor resistance of the back-
ground strain (data not shown).
Other Tumor Types in Pten+/− Mice
Because loss of Pten expression is associated with other tumor
types in addition to lung tumors, a panel of tissues was examined
in Pten+/− and +/+ mice in both the pseudo–A/J and C57BL/6 back-
grounds. Because Pten+/− mice are prone to spontaneous tumors
depending on background strain, it was thought that tumors not pre-
viously described for Pten+/− mice might arise in the pseudo–A/J
background. In addition, NNK-induced tumors might arise in tis-
sues other than the lungs for both strains. For these analyses, we in-
cluded tissues of known tumor development for Pten+/− mice as well
as tissues where human tumors have a documented tobacco contri-
bution (2004 Surgeon General’s Report—The Health Consequences
of Smoking). These included adrenal glands, cervical lymph nodes,
spleen, thymus, pancreas, kidneys, lungs, heart, liver, bladder, bone
marrow, colon, intestines, brain, and male and female reproductive
organs. No tumors other than lung tumors were observed for either
the Pten+/− or +/+ mice in the pseudo–A/J background with either
one or three doses of NNK, at 24 or 16 weeks after NNK injection,
respectively. However, 1 of 14 pseudo–A/J Pten+/−mice showed a ma-
lignant lung adenocarcinoma, whereas no carcinomas were observed in
the 11 +/+ littermate lungs evaluated. This contrasted with the
C57BL/6 background in which NNK-treated Pten+/− mice did not
develop lung tumors.
Fewer Pten+/− males than expected were obtained in the C57BL/6
background, which is consistent with previous reports [15]. Conse-
quently, the C57BL/6 NNK-treated Pten+/− group consisted of
mostly females. All Pten+/− mice in this background developed at
least one tumor, with or without NNK treatment. Most of these
tumors have been described previously in Pten+/− mice (Table 1).
NNK treatment did not alter tumor/hyperplasia incidence or severity
in Pten+/− mice, although one of nine NNK-treated mice developed
a liver hemangiosarcoma, a malignant tumor type not observed in
the spontaneous group or described previously in Pten+/− mice. Of
13 C57BL/6 Pten+/− mice in the spontaneous and NNK groups, 12
developed adrenal phenochromocytoma by 36 weeks of age. Prostate
tumors were observed in all Pten+/− males (1/1 with four in-
dependent adenomas in the NNK group, 2/2 with adenoma in spon-
taneous group, one of these with a concurrent carcinoma). Severe
lymphoid hyperplasia of the cervical lymph nodes was observed in
all Pten+/− mice in both NNK and spontaneous groups. Although
lymph nodes were generally 1 cm or larger in diameter (data not
shown), none were classified as lymphoma on histologic evaluation.
In addition, areas of severe uterine hyperplasia were observed in some
Pten+/− females in the absence of any endometrial tumors, which
have been described for Pten+/− mice in a CD-1 background [15].
Pten Expression Is Retained in Lung Tumors from
Pten+/− Mice
Loss of Pten hemizygosity has been reported in several spontane-
ous tumor types in Pten+/− mice [10,15,16,20]. Complete or al-
lelic loss of Pten has been described in human lung tumors [21],
although no lung tumors have been reported in Pten+/− mice. In
NNK-treated Pten+/− mice, no increase in lung tumor number was
observed, and Pten expression was not lost in 17 lung tumors from
eight pseudo–A/J Pten+/− mice (Figure 3). Lung tumors (Figure 3B)
and normal lung tissue (data not shown) from Pten+/− mice showed
decreased Pten protein expression when compared with +/+ mice. Al-
though Pten can down-regulate the Akt pathway, decreased Pten lev-
els in Pten+/− mice did not seem to affect Akt pathway activation in
lungs, because pAkt and pS6 levels were similar in tumors (Figure 3C )
and normal tissue (data not shown) from +/+ and Pten+/− mice.
Lung Tumors from Pten+/− Mice Harbor K-ras Mutations
at the Expected Frequency
NNK-induced lung tumors in A/J mice have been linked to mu-
tations in K-ras [22]. Because Pten allelic loss is associated with lung
tumors in humans, it was thought that Pten+/− mice might develop
NNK-induced lung tumors in the absence of K-ras mutations. How-
ever, similar frequencies of K-ras mutations were found in lung tu-
mors from Pten+/− mice compared with tumors from their +/+
littermates. Of 17 lung tumors from eight Pten+/− mice, 15 carried
a K-ras exon 1 mutation; whereas of 20 lung tumors from eight +/+
littermates, 15 carried a K-ras exon 1 mutation (Figure 3A; data not
shown). This is similar to published results for exon 1 K-ras muta-
tions in lung tumors from NNK-treated A/J mice [23].
Discussion
Although lung cancer is the major tobacco-associated neoplasm,
tobacco use contributes to other tumor types in humans. How-
ever, in mice, no tobacco carcinogen–associated tumors have been
Table 1. Pathologic Findings from Pten+/− and +/+ Mice.
NNK
Pten+/− +/+
Pseudo–A/J background
Lung adenoma 11/14* 10/11*
Lung adenocarcinoma 1/14 0/11
Spontaneous NNK
Pten+/− +/+ Pten+/− +/+
C57BL/6 background
Benign pheochromocytoma 3/4 0/5 8/9 0/5
Malignant pheochromocytoma 1/4 0/5 0/9 0/5
Prostate adenoma 2/2 0/5 1/1 0/5
Prostate carcinoma 1/2 0/5 0/1 0/5
Liver hemangiosarcoma 0/4 0/5 1/9 0/5
Severe lymphoid hyperplasia 4/4 1/5 9/9 0/5
Severe uterine hyperplasia 1/2 0/5 3/7 0/5
In the pseudo–A/J strain background, mice were treated with three doses of NNK and evaluated at
16 weeks after the first injection. In the C57BL/6 strain background, mice were treated with a
single dose of NNK and evaluated at 30 weeks after treatment. Values indicate the number of mice
affected/total mice evaluated. For prostate and uterine lesions, denominators reflect only males and
females, respectively. For prostate, only one of two C57BL/6 Pten+/− males treated with NNK had
tissue for evaluation.
*From surface lung tumor counts for this group, 16/17 Pten+/− and 14/14 Pten+/+ had visible
lung tumors (Figure 2).
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described in tissues other than in the lung. Pten alteration, by loss of
heterozygosity, mutation, or methylation, is common in human lung
cancer [9,21] and in other tumor types [24]. Humans and mice with
germline Pten alteration develop multiple spontaneous tumor types
[6,25], but sensitivity to tobacco carcinogens is unknown. For these
reasons, Pten+/− mice were investigated as a potential model for
tobacco carcinogen–induced tumorigenesis in lung and in other tis-
sues. Consistent with previous publications, we found that spontane-
ous tumor types in Pten+/− mice were highly dependent on strain
background. The pseudo–A/J strain was resistant to all tumors pre-
viously described for Pten+/− mice and did not show any sponta-
neous tumors other than in the lungs. In contrast, no lung tumors
were observed in C57BL/6 Pten+/− mice, although nearly all devel-
oped adrenal tumors, consistent with previous studies for a mixed
C57BL/6 background [17]. NNK had no effect on incidence or
severity of non–lung lesions in C57BL/6 mice, although a single
Pten+/− NNK-treated mouse developed a liver hemangiosarcoma,
a tumor type not previously described for Pten+/− mice. This implies
that NNK does not substantially cooperate with Pten allelic loss in
tumorigenesis. However, the considerable difference in tumor spec-
trum between the two strains highlights the effects of other, as yet
undetermined genes that can modify tumorigenesis in Pten+/− mice.
Such phenotypic variation is consistent with the phenotypic spec-
trum of patients with Cowden disease characterized by germline Pten
mutations. In Cowden disease, symptoms and severity vary widely
[25], which may reflect the contribution of polymorphisms in other
loci that modify the effect of Pten mutation in specific tissues. Over-
all, strain differences in genetically engineered mice are common and
highlight the need to investigate mouse models of human disease in
multiple background strains [14].
Decreased or absent Pten protein expression is common in human
lung adenocarcinomas and is associated with poor prognosis [3,26].
However, biallelic mutation or loss of Pten have not been associated
with K-ras mutations in lung tumors. In mice, homozygous deletion
of Pten in lung type II cells led to malignant lung tumors starting at
1 year of age and in an increase in urethane-induced lung tumors [8],
which have been shown previously to be highly associated with K-ras
mutation [27]. In another study, homozygous Pten deletion in bron-
chial epithelium Clara cells did not lead to any spontaneous lung
tumors in mice up to 1 year of age but did increase the malignancy
of lung tumors in a genetic model of mutant K-ras [9]. The two stud-
ies described involved K-ras mutation coincident with total deletion
Figure 3. Pten and K-ras status of lung tumors from NNK-treated or untreated Pten+/− and +/+ mice. (A) Representative Pten immuno-
histochemistry staining (visualized using an IR800 secondary antibody) and DNA staining (To-pro3-iodide). Slides were scanned at
1× using a 21-μm resolution on an Odyssey infrared scanner, and portions were enlarged to show detail. Each panel shows approxi-
mately one-third of the left lung lobe. Tumors are indicated with arrows. (B) Relative Pten staining from Pten+/− and +/+, NNK-induced
lung tumors. (C) Equivalent Akt pathway activation in lung tumors from Pten+/− and +/+ mice as determined by pS473-Akt and pS235/
236 S6 staining. Quantitation methods are described in the Materials and Methods section. (D) K-ras mutation was determined by Sur-
veyor Mutation Detection kit. K-ras mutation in exon 1 is seen as cleaved DNA in lanes marked “M.” Nonmutated K-ras does not show
any cleaved product in the wild type (wt).
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of Pten in only specific lung cell types and lung tumors. This is in
contrast to the studies described here where one copy of Pten was re-
tained in all tissues and was not lost in any mutant K-ras–containing
lung tumors. The absence of increased lung tumorigenesis in Pten+/−
mice supports the hypothesis that decreased Pten expression is in-
volved in the progression of lung tumors rather than in their initia-
tion. This is in contrast to the effects observed in other tissues such as
the intestines, breast, and endometrium, where Pten heterozygosity
leads to increased tumors [10,15] with frequent loss of the remain-
ing Pten allele [15]. Although normal lung tissues from pseudo–A/J
Pten+/− mice show decreased expression of Pten protein compared
with +/+ lungs, NNK-induced lung tumors in these mice retain the
expression of Pten (Figure 3). Because NNK did not increase lung
tumor incidence in Pten+/− mice, this suggests either that the loss
of the second Pten allele does not occur at a high frequency in lung
tissue or that there is no selective advantage for total Pten loss in
mouse lung tumors. Because homozygous Pten deletion seems to en-
hance the malignancy of mutant K-ras harboring lung tumors [8,9], it
is more likely that loss of the second copy of Pten is an infrequent
event in mouse lung tumors. However, the increased size of lung tu-
mors in the three-dose NNK pseudo–A/J group suggests that even
deletion of a single copy of Pten may enhance the growth of tumors
in the presence of other genetic changes.
The Akt pathway is considered an important target for Pten with
loss of Pten phosphatase activity leading to increased PIP3, which ac-
tivates Akt. Mutant K-ras activates PI3K, which also leads to increased
PIP3 and Akt activation. Recently, homozygous deletion of PI3K was
shown to prevent K-ras–induced lung tumors, suggesting that Akt
pathway activation is required for K-ras–driven lung tumorigenesis
[28]. Inhibition of downstream Akt signaling, with the mTOR inhibi-
tor rapamycin, decreased NNK-induced lung tumors by 90% [1].
Here, Pten+/− and +/+ lung tumors showed similar Akt pathway ac-
tivation (Figure 3) suggesting that K-ras mutation alone is enough to
activate the pathway to initiate lung tumorigenesis and that deletion of
a single copy of Pten does not amplify this signal.
In inbred A/J mice, NNK-induced lung adenocarcinomas were
not observed until 25 weeks after treatment [29], and we have found
no adenocarcinomas among NNK-induced lung tumors from 15 in-
bred A/J mice [1]. Although only observed in one mouse, the pres-
ence of a malignant lung adenocarcinoma in a Pten+/− mouse at only
16 weeks after treatment suggests that loss of even a single allele of
Pten may lead to more aggressive tumors or shorter latency to adeno-
carcinoma after treatment with a tobacco carcinogen. This is also
supported by the larger lung tumor size in Pten+/− mice treated with
three doses of NNK. Studies are ongoing to address whether allelic
loss of Pten can lead to increased lung adenocarcinomas at later times
and whether this could be accompanied by the total loss of Pten.
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